The association between CHST9 rs1436904 polymorphism and DFS of TNBC patients was further examined by stratifying for age of onset, BMI, tumor size, lymph-node metastasis, histological type, histological grade, menopausal status, vascular invasion, breast or ovarian cancer history, surgical method, taxane/anthracycline-based chemotherapy and radiotherapy, respectively (Table 2 and Supplementary Table 3–7). This evidence concerns the gene CHST9 and ovarian carcinoma.